Astellas participates in the Global Health Innovative Technology Fund (GHIT Fund), a product development fund for global health R&D which is built on the strength of contributions from partners in the public, private, and civil sectors, to support the research and development of drugs, vaccines, diagnostics and other products for HIV/AIDS, Malaria, Tuberculosis, and other NTDs needed by the poorest of the poor in developing nations.
In the first phase of the GHIT Fund (from 2013 to 2017), the fund has invested approximately $ 100 million in over 60 global product development partnerships. Japanese innovation and capacities in pharmaceuticals have been directly and effectively leveraged to global health R&D from target research which is initial stage of drug discovery to clinical trials in South America and Africa.
Astellas contributes to resolving Access to Health issues through continuous participation as a partner in the second phase of the GHIT Fund (from 2018 to 2022).
